Clinical trials of antiangiogenic therapy in non-small cell lung cancer: Focus on bevacizumab and ZD6474

Expert Review of Anticancer Therapy

Volumn 6, Issue 4, 2006, Pages 545-551

  Morgensztern, Daniel ^a   Govindan, Ramaswamy ^a  

^a USA   (United States)

Author keywords

Antiangiogenic therapy; Bavacizumab; Non small cell lung cancer; ZD6474

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOOXYGENASE 2 INHIBITOR; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; PACLITAXEL; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VATALANIB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC ACTIVITY; ARTERY THROMBOSIS; ASTHENIA; BLEEDING; BONE MARROW TOXICITY; BRAIN HEMORRHAGE; CANCER SURVIVAL; CARCINOGENESIS; CAUSE OF DEATH; CLINICAL TRIAL; DEHYDRATION; DESQUAMATION; DIARRHEA; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; NAUSEA; NEUTROPENIA; OUTCOMES RESEARCH; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; THROMBOCYTOPENIA; UNITED STATES; VEIN THROMBOSIS; CONTROLLED CLINICAL TRIAL; LUNG TUMOR; METHODOLOGY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PIPERIDINES; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS;

EID: 33746284878     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.4.545     Document Type: Review

References (33)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin. 55(1), 10-30 (2005).
2. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003. J. Clin. Oncol. 22(2), 330-353 (2004).
3. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 346(2), 92-98 (2002).
4. Kelly K, Crowley J, Bunn PA Jr et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J. Clin. Oncol. 19(13), 3210-3218 (2001).
5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3), 353-364 (1996).
6. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (7070), 932-936 (2005).
7. Carmeliet P. Angiogenesis in health and disease. Nature Med. 9(6), 653-660 (2003).
8. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med. 333(26), 1757-1763 (1995).
9. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Med. 7(9), 987-989 (2001).
10. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005).
11. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J. Clin. Oncol. 20(18), 3906-3927 (2002).
12. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011-1027 (2005).
13. Shibuya M, Yamaguchi S, Yamane A et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5(4), 519-524 (1990).
14. Terman BI, Carrion ME, Kovacs E et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6(9), 1677-1683 (1991).
15. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20(21), 4368-4380 (2002).
16. Ferrara N, Gerber HP, Le Couter J. The biology of VEGF and its receptors. Nature Med. 9(6), 669-676 (2003).
17. Ion T, Hemo I, Itin A et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med. 1(10), 1024-1028 (1995).
18. Millauer B, Wizigmann-Voos S, Schnurch H et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72(6), 835-846 (1993).
19. Fayette J, Soria JC, Armand JP. Use of angiogenesis inhibitors in tumour treatment. Eur. J. Cancer 41(8), 1109-1116 (2005).
20. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93(20), 10595-10599 (1996).
21. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
22. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19(3), 843-850 (2001).
23. Margolin K, Gordon MS, Holmgren E et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 19(3), 851-856 (2001).
24. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22(11), 2184-2191 (2004).
25. Sandler AB, Gray R, Brahmer J et al. Randomized Phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial. Proc. Am. Soc. Clin. Oncol. 23 (16Suppl.), 4 (2005).
26. de Gramont A, Van Cutsem E. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. Oncology 69(S3), 46-56 (2005).
27. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
28. Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151(6), 1523-1530 (1997).
29. Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 9(4), 1546-1556 (2003).
30. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin. Cancer Res. 11(1), 397-405 (2005).
31. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J. Clin. Oncol. 23(11), 544-555 (2005).
32. Johnson BE, Ma P, West H et al. Preliminary Phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as first-line treatment in patients with NSCLC. Proc. Am. Soc. Clin. Oncol. 23(16S), 7102 (2005).
33. Heymach JV, Johnson BE, Rowbottom JA, Fidias P, Lu C, Prager D et al. A randomized, placebo-controlled Phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. Proc. Am. Soc. Clin. Oncol. 23 (16S), 3023 (2005).